Assessing risk of liver enzyme elevation in patients with immune-mediated diseases and different hepatitis B virus serostatus receiving anti-TNF agents: a nested case-control study

BACKGROUND: Liver enzyme elevation is an important and common adverse effect among patients with immune-mediated diseases who receive tumour necrosis factor inhibitors (anti-TNF), and has various causes. Hence, we evaluated the relative risks of developing liver enzyme elevation in anti-TNF users wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiu, Ying-Ming, Lai, Mei-Shu, Chan, K. Arnold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664916/
https://www.ncbi.nlm.nih.gov/pubmed/29089055
http://dx.doi.org/10.1186/s13075-017-1413-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664916/
https://www.ncbi.nlm.nih.gov/pubmed/29089055
http://dx.doi.org/10.1186/s13075-017-1413-y

Ejemplares similares